Clinical Trial Update: Study Evaluating the Long-Term Safety of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Subjects With Pain Associated With Diabetic Peripheral Neuropathy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating long-term safety of desvenlafaxine succinate sustained-release in subjects with pain associated with diabetic neuropathy; study termina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Neuropathy

Drugs mentioned

• Desvenlafaxine succinate sustained-release (Desvenlafaxine)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Diabetic Neuropathy, Painful | Phase 3 | Status: TERMINATED | Results posted: 2010-05-11